3 completed, 2 recruiting, 1 not yet recruiting. 4 Phase 2, 2 Phase 1, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Not applicable | 1 | Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow background treatment: new trials by email Literature Review of background treatment trials Research Report on background treatment
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Exploratory Study on the Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Moderate to Severe Primary Sjögren's Syndrome Blinatumomab, background treatment - Primary Sjögren's Syndrome (pSS) | Phase 2 | Not yet recruiting | Beijing Tongren Hospital | 12 | 2026-09-25 | 2026-10-01 |
| A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants TNP-2092 for injection, Vancomycin Hydrochloride for Injection (IA), Vancomycin Hydrochloride for Injection (IV) - Periprosthetic Joint Infection (PJI) | Phase 1 / Phase 2 | Recruiting | TenNor Therapeutics Inc. | 33 | 2025-04-03 | 2026-10-19 |
| ConsideRAte Study - Splenic Stimulation for RA Active Stimulation, Sham Stimulation, Baricitinib - Rheumatoid Arthritis | Not applicable | Recruiting | Galvani Bioelectronics | 28 | 2021-10-19 | 2024-05-22 |
| Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD) Dupilumab, Placebo, Background treatment - Atopic Dermatitis (AD) | Phase 2 | Completed | Regeneron Pharmaceuticals | 54 | 2013-12-31 | 2020-03-18 |
| Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer Carboplatin, background treatment - Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II | Phase 2 / Phase 3 | Completed | GBG Forschungs GmbH | 595 | 2011-08-01 | 2016-02-15 |
| Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis Placebo, Dupilumab, Background treatment - Atopic Dermatitis | Phase 1 | Completed | Regeneron Pharmaceuticals | 37 | 2011-07-31 | 2020-02-26 |
Dermatitis, Atopic (2) · Arthritis, Rheumatoid (1) · Carcinoma, Ductal, Breast (1) · Dry Eye Syndromes (1) · Inflammation (1) · Inflammatory Breast Neoplasms (1)
Regeneron Pharmaceuticals (2) · Beijing Tongren Hospital (1) · GBG Forschungs GmbH (1) · Galvani Bioelectronics (1) · TenNor Therapeutics Inc. (1)
China (2) · Germany (2) · United States (2) · Australia (1) · Canada (1) · Netherlands (1) · New Zealand (1)
Gunter von Minckwitz, MD, Prof (1)
PMID 24794243, PMID 25006719, PMID 25199759, PMID 25482871, PMID 25534375, PMID 28715532, PMID 30194992, PMID 31252032, PMID 42602670